Global Markets Direct’s, 'Spinal Cord Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinal Cord Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Cord Disorders. Spinal Cord Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Spinal Cord Disorders. - A review of the Spinal Cord Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spinal Cord Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Spinal Cord Disorders. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Spinal Cord Disorders pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Spinal Cord Disorders Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Spinal Cord Disorders 7 Spinal Cord Disorders Therapeutics under Development by Companies 9 Late Stage Products 10 Comparative Analysis 10 Discovery and Pre-Clinical Stage Products 11 Comparative Analysis 11 Spinal Cord Disorders Therapeutics - Products under Development by Companies 12 Companies Involved in Spinal Cord Disorders Therapeutics Development 13 Scil Technology Gmbh 13 Isotechnika Pharma Inc. 14 Daewoong Pharmaceutical Co., Ltd. 15 Omeros Corporation 16 Spinal Cord Disorders - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Molecule Type 18 Drug Profiles 20 DWP-431 - Drug Profile 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 KUR-115 - Drug Profile 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 GPR161 Antagonist - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 ST-01 - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 Spinal Cord Disorders Therapeutics - Drug Profile Updates 26 Spinal Cord Disorders Therapeutics - Dormant Products 27 Spinal Cord Disorders - Product Development Milestones 28 Featured News and Press Releases 28 Dec 17, 2012: Genervon Receives Notice From European Patent Office For Patents On Methods Of Treating Neuronal Disorders Using MNTF Peptides And Analogs Thereof 28 Nov 10, 2011: Seikagaku Announces Start Of Phase III Trial In Japan For SI-6603 28 Aug 10, 2011: Seikagaku Announces Additional Clinical Trial In Japan For SI-6603 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables
Number of Products Under Development for Spinal Cord Disorders, H2 2013 7 Products under Development for Spinal Cord Disorders - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Comparative Analysis by Late Stage Development, H2 2013 10 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11 Products under Development by Companies, H2 2013 12 Scil Technology Gmbh, H2 2013 13 Isotechnika Pharma Inc., H2 2013 14 Daewoong Pharmaceutical Co., Ltd., H2 2013 15 Omeros Corporation, H2 2013 16 Assessment by Monotherapy Products, H2 2013 17 Assessment by Stage and Molecule Type, H2 2013 19 Spinal Cord Disorders Therapeutics - Drug Profile Updates 26 Spinal Cord Disorders Therapeutics - Dormant Products 27
List of Figures
Number of Products under Development for Spinal Cord Disorders, H2 2013 7 Products under Development for Spinal Cord Disorders - Comparative Analysis, H2 2013 8 Products under Development by Companies, H2 2013 9 Late Stage Products, H2 2013 10 Discovery and Pre-Clinical Stage Products, H2 2013 11 Assessment by Monotherapy Products, H2 2013 17 Assessment by Molecule Type, H2 2013 18 Assessment by Stage and Molecule Type, H2 2013 19